CVS Caremark and Generation Health Inc. announced they will offer an integrated Genetic Benefit Management (GBM) service utilizing the industry's first Best Test Genetics Network for coordination of testing directed at tailoring prescriptions to members based on their DNA.

The initial product offering is available to CVS Caremark pharmacy benefit management services clients and focuses on thirteen drug therapies. For medications generally dispensed through PBM services, the target medications will include: Imuran, Nolvadex, Plavix, Tabloid, Tegretol, and Ziagen. The partnership will also initially focus on seven medications dispensed through CVS Caremark's specialty pharmacy business, including Pegasys and Copegus, for treatment of hepatitis C, as well as the following oncology drugs: Gleevec, Tasigna, Sprycel, Tarceva, and Tykerb.

For each drug therapy, testing will be coordinated through the industry's first Best Test Genetics Network, a preferred provider organization of diagnostic service providers that offer evidence-based genetic and molecular testing.

This integrated GBM service offering will be launched for a select group of CVS Caremark's PBM clients in the months ahead, with the product becoming available to all clients starting in January 2011. Additionally, the CVS Caremark and Generation Health collaboration will be expanding its GBM service offerings as is warranted by research and medical advances.

CVS Caremark acquired a majority interest in Generation Health in December 2009. However, Generation Health operates as an independent business from CVS Caremark offering a full range of GBM services to employers, health plans, and provider networks.